论文部分内容阅读
目的:探讨孟鲁司特钠在腹型过敏性紫癜患儿中的应用效果。方法:选取2012年3月至2015年7月于我院接受治疗的84例腹型过敏性紫癜患儿,按照随机数表法分为试验组和对照组各42例。对照组患儿给予常规治疗加丙种球蛋白,试验组患儿在对照组的基础上联合孟鲁司特钠咀嚼片进行治疗。记录两组患儿的临床疗效及复发情况,对两组患儿腹痛、血便、皮疹消退情况、呕吐情况等进行比较分析。结果:试验组皮疹消退时间短于对照组,差异有统计学意义(P<0.05)。试验组患儿腹痛缓解时间、呕吐缓解时间、血便消失时间分别为(2.8±0.7)d、(3.4±2.1)d、(4.8±0.6)d,对照组患儿腹痛缓解时间、呕吐缓解时间、血便消失时间分别为(5.5±1.7)d、(6.0±2.6)d、(10.1±1.3)d,两组比较差异均有统计学意义(P均<0.05)。治疗后3个月,试验组无复发,对照组复发4例(9.5%),差异有统计学意义(P<0.05);治疗后6个月,试验组复发2例(4.8%),对照组复发9例(21.4%),差异有统计学意义(P<0.05)。结论:孟鲁司特钠应用于腹型过敏性紫癜患儿可有效缓解症状,见效迅速,复发率较低。
Objective: To investigate the effect of montelukast sodium in children with idiopathic purpura. Methods: From March 2012 to July 2015 in our hospital 84 cases of children with abdominal Henoch-Schonlein purpura were divided into experimental group and control group according to the random number table method in 42 cases. Control children with conventional therapy plus gamma globulin, the experimental group in the control group based on the combination of montelukast sodium chewable tablets for treatment. The clinical efficacy and recurrence of the two groups were recorded. The abdominal pain, bloody stool, rash subsided and vomiting were compared between the two groups. Results: The test group rash subsided time shorter than the control group, the difference was statistically significant (P <0.05). The pain relieving time, vomiting relieving time and bloody stool disappearing time in the experimental group were (2.8 ± 0.7) days, (3.4 ± 2.1) days and (4.8 ± 0.6) days respectively. The pain relief time, vomiting relief time, The disappearance time of bloody stool was (5.5 ± 1.7) days, (6.0 ± 2.6) days and (10.1 ± 1.3) days, respectively. There was significant difference between the two groups (all P <0.05). At 3 months after treatment, there was no recurrence in the experimental group and 4 cases (9.5%) in the control group, with a significant difference (P <0.05). At 6 months after treatment, the experimental group relapsed in 2 cases (4.8% Recurrent in 9 cases (21.4%), the difference was statistically significant (P <0.05). Conclusion: Montelukast sodium in children with idiopathic Henoch-Schonlein purpura can effectively relieve symptoms, with rapid response and low recurrence rate.